

PG PRIX GALIEN USA  
NEW YORK  
OCTOBER, 28 2014



## THE GALIEN FOUNDATION | MISSION

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of Nobel laureates in medicine, and with the ethical leadership of Peace Prize winner Professor Elie Wiesel, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand the “the best of the best” in new medicines and diagnostics.

Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media. In addition to recognizing advances in promising therapies, the Prix Galien’s annual Pro Bono award for humanitarian achievements brings a unique focus to the intersection between science, business and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation, where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly **“from the bench to the bedside,”** on behalf of patients everywhere.

### A TRULY GLOBAL PROGRAM

Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health as well as from the emerging markets of the developing world. Our theme: better cross cultural contacts, harmonized regulation, internal business process improvements, new information technologies, and effective public-private partnerships can remove barriers to the commercialization of good medicines and expand access to these benefits to all who need them.

2014 will represent a new and exciting stage in the evolution of the Prix Galien as the pre-eminent **“force populaire”** behind the global scientific enterprise. With the support of our sponsoring organizations, our efforts will extend to all who see medical innovation not only as an industrial policy asset but as a source of social progress – where private enterprise and public engagement combine to deliver a greater public good.

We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.



## INNOVATION TO IMPROVE THE HUMAN CONDITION

The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology.

Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

# THE 2014 AWARDS COMMITTEE



**P. Roy VAGELOS, M.D.**

*Committee Chairman*

Chairman of Regeneron Pharmaceuticals; retired Chairman and Chief Executive Officer at Merck



**Richard AXEL, M.D.**

*Nobel Laureate*

Co-director, the Kavli Institute for Brain Science, Columbia University Medical Centre, New York.



**Michael S. BROWN, M.D.**

*Nobel Laureate*

Professor of Molecular Genetics and Internal Medicine, UT Southwestern Medical Center at Dallas



**Laurie GLIMCHER, M.D.**

Cornell Provost for Medical Affairs and Dean of the Medical College, New York.



**Joseph GOLDSTEIN, M.D.**

*Nobel Laureate*

Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center at Dallas



**Paul A. MARKS, M.D.**

Laboratory Head of Cell Biology, Memorial Sloan Kettering Cancer Center



**Bengt SAMUELSSON, M.D., Ph.D.**

*Nobel Laureate*

Professor, Karolinska Institutet Former President of Karolinska Institutet and Chairman of the Nobel Foundation



**Marc TESSIER-LAVIGNE, Ph.D.**

President, The Rockefeller University, New York, Professor Laboratory of Brain Development and Repair



**Elie WIESEL**

*Nobel Laureate*

University Professor and Professor of Philosophy and Religion, Boston University Honorary Member



# WHO WAS GALEN?



Born in 131AD, Galen (Galien in French) is considered the father of modern medicine and pharmacology. As an anatomist, physiologist, clinician and researcher, his work formed the basis of a school of thought known as “Galenism”, which dominated medicine until the Renaissance. In fact, Galen’s works were used as primary medical reference for nearly two centuries.

Raised in Pergamos, he studied in Smyrna, Corinth, and Alexandria, the three centers of medical excellence in the ancient world. Legend has it that Galen was visited by Aesclepius in a dream and that this inspired the direction of his life. When he was 17, Galen worked

as a physician to the gladiatorial school. At the age of 37, Marcus Aurelius summoned him to Rome, where he grew in reputation and stature as a healer, teacher, researcher and writer. His ideas on the functioning of the human body were so well received that he became the personal doctor of young Commodus, the heir to the Emperor. He died in 201AD. During his long and eminent career, Galen completed over five hundred learned works addressing anatomy, physiology, pathology, medical theory and practice, and many forms of therapy. He traveled throughout the world, studying local plants and remedies, eventually describing 473 original drugs and


many substances of mineral and vegetable origin. Importantly, Galen was the first to codify the art of preparing active drugs using multiple ingredients. Galen’s faculties of observation, logic and deduction made him the true successor of Hippocrates, and his declaration that the primary aim of medicine was patient care formed the very cornerstone of modern pharmacy. To quote Jean-Pierre Changeux, “Galen first showed that our mind was in the brain, not in our hearts.” It can be said that this was the beginning of experimental medicine.



## THE MEDAL BY ALBERT DE JAEGER

The Prix Galien medal was designed by Albert de Jaeger (1908 – 1992), laureate of the Premier Grand Prix de Rome architectural prize. De Jaeger designed medals for prominent figures such as Pope Pius XII (at the Villa Medici, 1937) and Pope Jean-Paul I, Presidents Dwight D. Eisenhower and John F. Kennedy, distinguished military leaders including Marshals Leclerc, Koenig, Montgomery, Marshall and Joukov; the Weizmann Institute, as well as numerous artists, literary figures and prominent personalities such as Sacha Guitry, Marcel Proust, Henri de Montherlant, Paul Harris, a number of Nobel Prize laureates, the Empress of Iran SA Farah Diba, Princess Grace of Monaco, and others...

*De Jaeger is also the architect of numerous outstanding monuments in France and throughout the world.*



# PRIX GALIEN USA

## AN UNRIVALED REPUTATION FOR INTELLECTUAL RIGOR AND INTEGRITY...

The Prix Galien USA Committee, a group of highly accomplished individuals from the scientific and research communities, will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.



**Elie Wiesel**, Peace Nobel Laureate, Honorary Member, Prix Galien USA Committee;

**BAN Ki-moon**, General Secretary, United Nations;

**Bill Clinton**, 2010 Prix Galien Pro Bono Humanum Award Laureate;

**Philippe Douste-Blazy**, 2010 Prix Galien Pro Bono Humanum Award Laureate

# 1970 to present THE PRIX GALIEN HALL OF FAME

WINNER	No. OF MEDALS	WINNER	No. OF MEDALS	WINNER	No. OF MEDALS
Merck	39	Sanofi-Pasteur MSD	14	Actelion, Alexion, Biogen, Celgene, Fresenius Biotech, Genzyme, Ipsen, Procter & Gamble, Teva	2
Roche	36	Amgen	12	Albana Pharma, Baxter, Biocodex, Boston Scientific, Chugai, Edwards LifeSciences, Ferrer, Guerbet, Institut Santa Creu, Leo, LFB, Lundbeck, Medtronic, Menarini, Orphan, Otsuka, PharmaPharm, Pierre Fabre, Service de Santé des Armées, Shine, Swedish Orphan International, Takeda, Uriach, Vertex, Viron Therapeutics	1
Novartis	34	BMS, Servier	10		
GlaxoSmithKline	33	Abbott, Merck-Serono	9		
Pfizer	27	Boehringer, Eli-Lilly, Inserm	5		
Sanofi	24	Astra-Zeneca, Vertex	4		
Johnson & Johnson	22	Almirall-Prodesfarma, Pasteur Institute	3		
Bayer-Schering Pharma	17				

## PRIX GALIEN USA WINNERS



## AND IN 2014 THE WINNERS ARE...

### 2013 Winners

- Best Pharmaceutical Agents:**  
Zelboraf® - Genentech
- Best Biotechnology Product:**  
Zostavax® - Merck
- Best Medical Technology product:**  
S-ICD® System - Boston Scientific
- Pro Bono Humanum Award:**  
Dr. Anthony S. Fauci

### 2012 Winners

- Best Pharmaceutical Agents:**  
Vitreolis® - Merck; Incivek® - Vertex
- Best Biotechnology Product:**  
Yervoy® - Bristol-Myers Squibb
- Best Medical Technology product:**  
Sapien® - Edwards Lifesciences  
Melody® - Medtronic
- Pro Bono Humanum Award:**  
Dr. Francis S. Collins

### 2011 Winners

- Best Pharmaceutical Agent:**  
Plevnar13® - Pfizer
- Best Biotechnology Product:**  
Stelara® - Janssen  
Prolia and XGEVA® - Amgen
- Pro Bono Humanum Award:**  
Paul Farmer

### 2010 Winners

- Best Pharmaceutical Agent:**  
Coartem® - Novartis
- Best Biotechnology Product:**  
RotaTeq® - Merck & Co.
- Best Medical Technology:**  
xTAC® - Luminex Corporation
- Pro Bono Humanum Award:**  
Bill Clinton and  
Philippe Douste-Blazy

### 2009 Winners

- Best Pharmaceutical Agent:**  
Gleevec® - Novartis
- Best Biotechnology Product:**  
Nplate® - Amgen; Promacta® - GSK
- Best Medical Technology:**  
Cellsearch® - Veridex (J&J)
- Pro Bono Humanum Award:**  
Jeffrey Sachs and Barry Bloom

### 2008 Winners

- Best Pharmaceutical Agent:**  
Isentress® - Merck; Selzentry® - Pfizer
- Best Biotechnology Product:**  
Soliris® - Alexion; Infuse® - Wyeth
- Special therapeutic development:**  
Revlimid® - Celgene
- Pro Bono Humanum Award:**  
Sheldon Segal

### 2007 Winners

- Best Pharmaceutical Agent:**  
Januvia® - Merck; Chantix® - Pfizer
- Best Biotechnology Product:**  
Humira® - Abbott; Gardasil® - Merck
- Pro Bono Humanum Award:**  
Dr. Roy Vagelos



# A RECORD OF LEADERSHIP IN BRINGING THE BEST OF BIOMEDICAL DISCOVERY TO THE ATTENTION OF THE WORLD...

## PRIX GALIEN AROUND THE GLOBE



### UNITED NATIONS

The Prix Galien is the right event, on the right issue at the right time. I thank the Galien Foundation for bringing us together and for recognizing that a healthier world is a safer world and a more just world.

**BAN Ki-moon**  
*Secretary-General - 2010*



### UNITED KINGDOM

It is a pleasure to congratulate all those who promote the Prix Galien and pharmaceutical research: they play a vital role in the fight against disease throughout the world.

**John Major**  
*Prime Minister - 1996*



### CANADA

The Prix Galien is a prestigious award, a magnificent occasion to pay recognition to our researchers and to encourage our industry.

**Jean Chretien**  
*Prime Minister - 1994*



### FRANCE

We recognize the importance of the Prix Galien in promoting drug research, and we salute the excellent work of the Jury.

**Philippe Douste-Blazy**  
*Minister of Foreign Affairs - 2006*



### SWITZERLAND

When Olympic rhymes with Galenic: there is a gold medal that can be won for an extraordinary achievement: this is the Galien Award, the Oscar of pharmaceutical research.

**Walter Sutter**  
*State Advisor, Director of the Public Economy - 2004*

## PRIX GALIEN IN THE USA



The Prix Galien is a welcome initiative to stimulate creative research and promote excellence.

**Barack Obama**  
*2008*



### To Dr. Roy Vagelos on receiving the Pro Bono Humanum Award

Rosalynn joins me in congratulating you on receiving the 2007 Galien Pro Bono Humanum Prize at the Prix Galien Awards Ceremony.

**Jimmy Carter**  
*2007*



Prix Galien recognizes men and women from the pharmaceutical and biomedical industries whose contributions of science have improved and saved countless lives.

**Michael Bloomberg**  
*2010*



I'd also like to congratulate all the candidates for the 5th Annual Prix Galien Awards Competition, which honors those in the pharmaceutical industry who have developed the technical, scientific and clinical research skills necessary to develop innovative medicines and devices. Your work is invaluable.

**Margaret A. Hamburg, M.D.**  
*Commissioner of Food and Drugs Food and Drug Administration - 2011*



The Prix Galien USA recognizes the important research necessary to develop innovative medicines and devices that have a life-saving impact on individuals and families across the globe.

**Kathleen Sebelius**  
*Secretary of Health and Human Services - 2011*




# GALIEN AWARDS CEREMONY

OCTOBER 28, 2014  
6:00 PM

AMERICAN MUSEUM OF NATURAL HISTORY,  
NEW YORK CITY


Our annual gala awards dinner is a creative recognition of the productive and positive power of partnerships that drive progress in medical science. It is peer exchange with a public purpose - with a diverse range of opportunities for contact with a range of interests, from professional and scientific groups, academia and governments to patient associations, other non-profit organizations and the media.





# THE PRO BONO HUMANUM AWARD

The committee follows a century-old example set in Sweden. The Prix Galien rewards excellence and novelty, and awards special honors to those who have served humanity at large. The Pro Bono Humanum Award recognizes exemplary and innovative efforts in improving the human condition. This special award is presented by Elie Wiesel, in presence of the Prix Galien USA Committee.



**2013**

**Dr. Anthony Fauci** for his paramount contributions to basic and clinical research on the pathogenesis and treatment of immunemediated and infectious diseases. He currently serves as Director of the NIAID and chief of the NIAID Laboratory of Immunoregulation in Bethesda, Maryland.



**2012**

**Dr. Francis S. Collins.** Dr. Collins, Director of the National Institutes of Health (N.I.H) In recognition of his contribution to the ethical implications of scientific research



**2011**

**Pr. Paul Farmer** in recognition of his heroic efforts to do "whatever it takes" to improve the lives and health of patients in destitute communities around the world through the Partners in Health initiative which he co-founded with Tom White.



**2010**

**Bill Clinton** and **Philippe Douste-Blazy**, in recognition of their outstanding achievements in providing treatment for underserved populations through the William J. Clinton Foundation HIV / AIDS Initiative and the multilateral organization, UNITAID.



**2009**

Harvard Professor **Barry Bloom** for bringing the fruits of basic biological science to those who are most needy. Columbia University Earth Institute Director **Jeffrey Sachs** for bringing the fruits of scholarly economics to bear our problems that have plagued the world for millennia.



**2008**

**Sheldon Segal** and the **Population Council** for their global efforts in support of reproductive health and family planning.



**2007**

Former Merck CEO **Roy Vagelos**, for the River Blindness Program and his historic decision to donate the drug Mectizan® to more than 530 million people in 34 countries to treat and prevent river blindness: "as much as necessary for as long as necessary."

# GALIEN FORUM

## OCTOBER 28, 2014

### 7:30 AM

ALEXANDRIA CENTER FOR LIFE SCIENCE,  
NEW YORK CITY

#### **The Brain Initiative**

Modeled on the Human Genome Project, this joint US public-private research initiative has an ambitious goal: to unlock the secrets to the way humans think, learn and remember and, in doing so, advance the progress of medical treatments and cures for a host of crippling diseases, including senile dementia, epilepsy, Parkinson's, schizophrenia, and autism.

The Forum panel will provide one of the first timely updates since formal announcement of the Initiative in April 2013, with the added advantage of a discussion among leading industry scientists on how research into neurological disorders is benefiting from a new wave of genetic, stem cell and nanoparticle technologies.

#### **Heart Attack Guidelines**

*Definitions, Big Data and Diagnosis:*

*Cardiologist Guidelines for Heart Disease*

Incontrovertible evidence from animal experiments, human genetics, epidemiology and therapeutics has established plasma low density lipoprotein (LDL) as the instigating factor in the epidemic of heart attacks that has engulfed the industrialized world. We have the capacity, through diet and drugs, to lower LDL levels and reduce heart attacks. Three questions remain: 1) who to treat, 2) when to treat, and 3) how aggressively to treat? Recently, an advisory panel of the American Heart Association and the American College of Cardiology issued guidelines that address these issues. The new guidelines depart radically from previous guidelines issued by a predecessor panel, and they have proved to be controversial.

The Prix Galien Forum panel will tackle this controversy through a dialogue among leading experts in the epidemiology, genetics and physiology of heart attacks, and in the clinical trials that influenced the new guidelines. Out of this discussion we hope that a new consensus may emerge, and that the three therapeutic questions will be answered.



## 2014 PRELIMINARY PROGRAM

**The Brain Initiative** - Chair: *Richard Axel\**

**Heart Attack Guidelines** - Chair: *Michael S. Brown*

**Obamacare: 1 year after** - Chair: *Roy Vagelos*

**Cancer Immunotherapeutics** - Chair: *Laurie Glimcher*

**Global Health** - Chair: *Bengt Samuelsson*

\* TBC



The mission of the Galien Foundation is to serve as a vehicle for the open exchange of ideas that drive science and new innovations. Our fifth major forum will be held at the Alexandria Center for Life Science on the day of October 28th, 2014, and will feature round table debates focusing on critical, global healthcare issues and challenges.

As a sponsor of the Prix Galien, your company will have an array of opportunities to network with global healthcare decision makers, policy makers, academicians, and the Prix Galien committee. Collaboration with the Prix Galien allows you to participate in and impact the discussions as a thought leader around the most critical global healthcare issues.



### **US Health Reform: The New Normal?**

2014 was designed as the critical year for implementation of the most sweeping piece of health care legislation in US history. Clearly, the pace of phase-in has slowed, particularly in terms of enforcement of the individual mandate as well as the obligations on employers to participate. With the mid-term congressional elections – and party control of the Senate and House – taking place just one week after the Forum, the ultimate fate of reform looks to be hanging in the balance. To assess the prospects for the Affordable Care Act going forward, the Forum will convene CEOs from the innovative drug industry, key Administration officials and a representative from the payer community. A single point of consensus is not guaranteed.

### **Cancer Immunotherapeutics**

As understanding of the genetic origins of cancers continues to expand, there are more opportunities to explore strategies to isolate and kill tumor cells without distorting or damaging healthy tissue. Perhaps the most revolutionary and promising area is mobilizing the body's natural immune system to deny cancerous cells the ability to proliferate out of control. This panel will review the role that drugs and vaccines may play in generating this response, particularly as the research community begins to digest learnings from recent advances in genomics and computational biology.

### **A New Agenda for Global Health**

Health is central to development, and development is a global issue that is “multi” in every sense of the word. With the Millennium Development Goals reaching their 2015 deadline for completion, what new themes, strategies, tactics and institutions are necessary to maintain the momentum behind the World Health Organization's [WHO] still unfinished promise of “Health for All?” What can be done to foster the growth of more “creative coalitions” that fight disease with multiple stakeholders working toward a common goal. A panel of leaders drawn from science, industry, and government, will identify elements of a new action agenda.



## THEY PARTICIPATED IN THE ANNUAL GALIEN FORUM:

**Dr. David Altshuler,**  
Massachusetts General Hospital  
and Broad Institute

**Dr. Christopher Austin,**  
Director, National Center  
for Advancing Translational  
Sciences, National  
Institutes of Health

**Dr. Alice d'Autry,**  
President, Institut Pasteur

**Dr. Samantha Budd,**  
Vice President, Neuroscience  
iMed at AstraZeneca R&D

**Dr. Robert M. Califf,**  
Vice Chancellor for Clinical and  
Translational Medicine, Director  
of the Duke Translational  
Medicine Institute (DTMI), and  
Professor of Medicine in the  
Division of Cardiology Duke  
University

**John J. Castellani**  
President and CEO, the  
Pharmaceutical Research and  
Manufacturers of America  
(PhRMA)

**Dr. Mikael Dolsten,**  
President Worldwide Research  
and Development, Pfizer Inc

**Kenneth C. Frazier,**  
Chairman, CEO and President,  
Merck

**Dr. Alex Gorsky,**  
Chairman and CEO,  
Johnson & Johnson

**Margaret Hamburg,**  
Commissioner of Food and  
Drugs, U.S. Food and Drug  
Administration

**Dr. David Holtzman,**  
Andrew B. and Gretchen P.  
Jones Professor and Chairman  
of Neurology, Professor of  
Developmental Biology,  
Associate Director of the  
Alzheimer's Disease Research  
Center, Washington University

**Herve Hoppenot,**  
President Novartis Oncology,  
Novartis Pharmaceuticals  
Corporation

**Dr. Kris Joshi,**  
Global Vice President,  
Healthcare Oracle  
Health Sciences

**Dr. Carl H. June,**  
Director of Translational  
Research at the Abramson  
Cancer Center at the University  
of Pennsylvania

**Dr. Mark Kris,**  
Chief, Thoracic Oncology  
Services, Memorial  
Sloan-Kettering  
Cancer Center

**Dr. John Lechleiter,**  
Chairman and CEO,  
Eli Lilly & Company

**Dr. Jeffrey Leiden,**  
Chairman, President and CEO,  
Vertex

**Dr. Richard Lifton,**  
Professor, Yale University  
School of Medicine

**Dr. Jan Lundberg,**  
Executive Vice President,  
Science and Technology  
and President,  
Lilly Research Labs, Lilly & Co.

**Joel S. Marcus,**  
Chairman, Alexandria

**Dr. Ira Mellman,**  
Vice President, Research  
Oncology, Genentech

**Dr. John Thomas Potts,  
Jr.,** Distinguished Jackson  
Professor of Clinical Medicine,  
Massachusetts General Hospital  
and Harvard Medical School

**Dr. Michael Rosenblatt,**  
Executive Vice President and  
Chief Medical Officer, Merck

**Dr. Jonathan Sheldon,**  
Global Senior Director of  
Translational Medicine, Oracle  
Health Sciences

**Dr. Morgan Sheng,**  
Vice President, Neuroscience,  
Genentech

**Dr. Elliott Sigal,**  
Former Executive Vice President,  
Chief Scientific Officer and  
President, R&D, BMS

**Dr. Reisa Sperling,**  
Professor of Neurology at  
Harvard Medical School  
Department of Neurology,  
Brigham and Women's Hospital

**Guido Rasi,**  
Executive Director, European  
Medicines Agency

**Dr. Bert Vogelstein,**  
Professor, Johns Hopkins School  
of Medicine

**Dr. Huda Zoghbi,**  
Professor, Baylor College of  
Medicine



# JOIN US!



The Galien Foundation  
60 Broad Street, Suite 3502/KVB  
New York, New York 10004  
212-685-1592

[www.galienfoundation.org](http://www.galienfoundation.org)